U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C13H13N3O3
Molecular Weight 259.2611
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LENALIDOMIDE

SMILES

c1cc2c(CN(C3CCC(=NC3=O)O)C2=O)c(c1)N

InChI

InChIKey=GOTYRUGSSMKFNF-UHFFFAOYSA-N
InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)

HIDE SMILES / InChI

Molecular Formula C13H13N3O3
Molecular Weight 259.2611
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment:: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/22966948 http://www.revlimidrems.com/

Lenalidomide (trade name Revlimid) is a derivative of thalidomide introduced in 2004. It is an immunomodulatory agent with anti-angiogenic properties. Revlimid in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma (MM) who have received at least one prior therapy. Also is indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. In addition, Revlimid is indicated for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib. The mechanism of action of lenalidomide remains to be fully characterized. Lenalidomide inhibited the secretion of pro-inflammatory cytokines and increased the secretion of anti-inflammatory cytokines from peripheral blood mononuclear cells. Lenalidomide causes a delay in tumor growth in some in vivo nonclinical hematopoietic tumor models including multiple myeloma. Immunomodulatory properties of lenalidomide include activation of T cells and natural killer (NK) cells, increased numbers of NKT cells, and inhibition of pro-inflammatory cytokines (e.g., TNF-α and IL-6) by monocytes. In multiple myeloma cells, the combination of lenalidomide and dexamethasone synergizes the inhibition of cell proliferation and the induction of apoptosis. Recently was discovered, that protein cereblon (CRBN) is a proximate, therapeutically important molecular target of lenalidomide. Low CRBN expression was found to correlate with drug resistance in multiple myeloma (MM) cell lines and primary MM cells. One of the downstream targets of CRBN identified is interferon regulatory factor 4 (IRF4), which is critical for myeloma cell survival and is down-regulated by (immune-modulatory drugs) treatment. CRBN is also implicated in several effects of immunomodulatory drugs, such as down-regulation of tumor necrosis factor-α (TNF-α) and T cell immunomodulatory activity, demonstrating that the pleotropic actions of the immunomodulatory drugs (IMiDs) are initiated by binding to CRBN. Future dissection of CRBN downstream signaling will help to delineate the underlying mechanisms for IMiD action and eventually lead to development of new drugs with more specific anti-myeloma activities. It may also provide a biomarker to predict IMiD response and resistance. Lenalidomide also inhibited the expression of cyclooxygenase-2 (COX-2) but not COX-1 in vitro.

CNS Activity

Curator's Comment:: CSF-to-plasma ratio for lenalidomide of 0·10. In comparison to drugs whose CNS activity is known, lenalidomide has moderate CNS penetrability.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Q96SW2
Gene ID: 51185.0
Gene Symbol: CRBN
Target Organism: Homo sapiens (Human)
3.0 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
REVLIMID

Approved Use

REVLIMID is a thalidomide analogue indicated for the treatment of patients with: Multiple myeloma (MM), in combination with dexamethasone (1.1). Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities (1.2). Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib (1.3). Limitations of Use: REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials (1.4). 1.1 Multiple Myeloma REVLIMID in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma (MM). 1.2 Myelodysplastic Syndromes REVLIMID is indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. 1.3 Mantle Cell Lymphoma REVLIMID is indicated for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib. 1.4 Limitations of Use: REVLIMID is not indicated and is not recommended for the treatment of patients with CLL outside of controlled clinical trials [see Warnings and Precautions (5.5)

Launch Date

1.13564162E12
Primary
REVLIMID

Approved Use

REVLIMID is a thalidomide analogue indicated for the treatment of patients with: Multiple myeloma (MM), in combination with dexamethasone (1.1). Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities (1.2). Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib (1.3). Limitations of Use: REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials (1.4). 1.1 Multiple Myeloma REVLIMID in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma (MM). 1.2 Myelodysplastic Syndromes REVLIMID is indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. 1.3 Mantle Cell Lymphoma REVLIMID is indicated for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib. 1.4 Limitations of Use: REVLIMID is not indicated and is not recommended for the treatment of patients with CLL outside of controlled clinical trials [see Warnings and Precautions (5.5)

Launch Date

1.13564162E12
Primary
REVLIMID

Approved Use

REVLIMID is a thalidomide analogue indicated for the treatment of patients with: Multiple myeloma (MM), in combination with dexamethasone (1.1). Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities (1.2). Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib (1.3). Limitations of Use: REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials (1.4). 1.1 Multiple Myeloma REVLIMID in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma (MM). 1.2 Myelodysplastic Syndromes REVLIMID is indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. 1.3 Mantle Cell Lymphoma REVLIMID is indicated for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib. 1.4 Limitations of Use: REVLIMID is not indicated and is not recommended for the treatment of patients with CLL outside of controlled clinical trials [see Warnings and Precautions (5.5)

Launch Date

1.13564162E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
433.1 ng/mL
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LENALIDOMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1252.08 ng/mL
2 mg/kg single, oral
dose: 2 mg/kg
route of administration: oral
experiment type: single
co-administered:
LENALIDOMIDE plasma
Homo sapiens
population: unhealthy
age: Children
sex:
food status:
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1472.4 ng × h/mL
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LENALIDOMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
5378.83 ng*h/mL
2 mg/kg single, oral
dose: 2 mg/kg
route of administration: oral
experiment type: single
co-administered:
LENALIDOMIDE plasma
Homo sapiens
population: unhealthy
age: Children
sex:
food status:
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3 h
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LENALIDOMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
70%
LENALIDOMIDE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
25 mg 1 times / day multiple, oral
Highest studied dose
Dose: 25 mg, 1 times / day
Route: oral
Route: multiple
Dose: 25 mg, 1 times / day
Sources:
unhealthy, 35 years (range: 20-70years)
n = 3
Health Status: unhealthy
Condition: Relapsed or Refractory Classical Hodgkin Lymphoma
Age Group: 35 years (range: 20-70years)
Sex: M+F
Population Size: 3
Sources:
10 mg 1 times / day steady, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
pregnant, adult
Health Status: pregnant
Age Group: adult
Sex: F
Sources:
Other AEs: Birth defects...
10 mg 1 times / day steady, oral (starting)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources: Page: p. 101
unhealthy, adult
n = 395
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 395
Sources: Page: p. 101
Disc. AE: Thrombocytopenia, Neutropenia...
AEs leading to
discontinuation/dose reduction:
Thrombocytopenia (6.1%)
Neutropenia (3.5%)
Rash (2%)
Nausea (1.5%)
Diarrhea (1.3%)
Fatigue (1%)
Anaemia NOS (1%)
Abdominal distension (1%)
Pyrexia (0.8%)
Dyspnea (0.8%)
Cough (0.5%)
Abdominal pain NOS (0.5%)
Face edema (0.5%)
Pruritus (0.5%)
Anemia hemolytic (NOS) (0.5%)
Pneumonia NOS (1%)
Arthralgia (0.5%)
Sources: Page: p. 101
10 mg 1 times / day steady, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Other AEs: Neutropenia, Thrombocytopenia...
Other AEs:
Neutropenia
Thrombocytopenia
Thrombosis venous deep
Pulmonary embolism
Sources:
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 87
Health Status: unhealthy
Condition: Complex Regional Pain Syndrome
Population Size: 87
Sources:
Other AEs: Joint sprain, Foot fracture...
Other AEs:
Joint sprain (serious, 2 patients)
Foot fracture (serious, 1 patient)
Thrombosis (serious, 1 patient)
Blood human chorionic gonadotropin positive (serious, 1 patient)
Blood potassium decreased (serious, 1 patient)
Pregnancy test false positive (serious, 1 patient)
Sick sinus syndrome (serious, 1 patient)
Pregnancy NOS (serious, 2 patients)
Abortion spontaneous NOS (serious, 1 patient)
Pain NOS (serious, 1 patient)
Arthritis NOS (serious, 1 patient)
Angioneurotic edema (serious, 1 patient)
Rash NOS (below serious, 24 patients)
Pruritus (below serious, 8 patients)
Dry skin (below serious, 6 patients)
Diarrhoea NOS (below serious, 11 patient)
Constipation (below serious, 8 patients)
Vomiting NOS (below serious, 5 patients)
Dizziness (below serious, 9 patients)
Pyrexia (below serious, 6 patients)
Nasopharyngitis (below serious, 6 patients)
Pharyngitis (below serious, 6 patients)
Sinusitis NOS (below serious, 5 patients)
Alanine aminotransferase increased (below serious, 5 patients)
Cramp muscle (below serious, 5 patients)
Insomnia (below serious, 7 patients)
Sources:
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Other AEs: Fatigue, General physical health deterioration...
Other AEs:
Fatigue (serious, 1 patient)
General physical health deterioration (serious, 2 patients)
Mucosal inflammation (serious, 1 patient)
Pneumonia (serious, 3 patients)
Anal abscess (serious, 1 patient)
Bacteraemia (serious, 1 patient)
Cellulitis (serious, 1 patient)
Erysipelas (serious, 1 patient)
Gastroenteritis (serious, 1 patient)
Pneumonia legionella (serious, 1 patient)
Pyelonephritis (serious, 1 patient)
Septic shock (serious, 2 patients)
Urinary tract infection (serious, 1 patient)
Epistaxis (serious, 1 patient)
Lung disorder (serious, 1 patient)
Pulmonary embolism (serious, 2 patients)
Acute myeloid leukaemia (serious, 8 patients)
Bladder cancer (serious, 1 patient)
Breast cancer (serious, 1 patient)
Colon cancer (serious, 1 patient)
Colorectal cancer (serious, 1 patient)
Histiocytosis haematophagic (serious, 1 patient)
Refractory anaemia with an excess of blasts (serious, 2 patients)
Confusional state (serious, 1 patient)
Delirium (serious, 1 patient)
Altered mood (serious, 1 patient)
Acute myocardial infarction (serious, 2 patients)
Cardiac failure (serious, 1 patient)
Myocardial infarction (serious, 1 patient)
Tachyarrhythmia (serious, 1 patient)
Abdominal pain (serious, 1 patient)
Abdominal pain upper (serious, 1 patient)
Colitis (serious, 1 patient)
Constipation (serious, 1 patient)
Diarrhoea (serious, 3 patients)
Intestinal obstruction (serious, 1 patient)
Femoral neck fracture (serious, 1 patient)
Humerus fracture (serious, 1 patient)
Spinal compression fracture (serious, 1 patient)
Subdural haematoma (serious, 1 patient)
Synovial rupture (serious, 1 patient)
Hyperglycaemia (serious, 1 patient)
Cerebral haemorrhage (serious, 1 patient)
Cerebrovascular accident (serious, 1 patient)
Coma (serious, 1 patient)
Headache (serious, 1 patient)
Colic renal (serious, 1 patient)
Renal failure (serious, 1 patient)
Stress urinary incontinence (serious, 1 patient)
Deep vein thrombosis (serious, 4 patients)
Arterial occlusive disease (serious, 1 patient)
Hypotension (serious, 1 patient)
Orthostatic hypotension (serious, 1 patient)
Anaemia (serious, 1 patient)
Autoimmune thrombocytopenia (serious, 1 patient)
Bone marrow failure (serious, 1 patient)
Febrile neutropenia (serious, 2 patients)
Haemolysis (serious, 1 patient)
Neutropenia (serious, 5 patients)
Pancytopenia (serious, 1 patient)
Splenomegaly (serious, 1 patient)
Thrombocytopenia (serious, 3 patients)
Arthritis (serious, 1 patient)
Back pain (serious, 2 patients)
Joint range of motion decreased (serious, 1 patient)
Musculoskeletal pain (serious, 1 patient)
Skin ulcer (serious, 1 patient)
Urticaria (serious, 1 patient)
Diarrhoea (below serious, 37 patients)
Nausea (below serious, 21 patient)
Constipation (below serious, 19 patients)
Abdominal pain (below serious, 14 patients)
Vomiting (below serious, 9 patients)
Dry mouth (below serious, 5 patients)
Abdominal pain upper (below serious, 8 patients)
Dyspepsia (below serious, 5 patients)
Flatulence (below serious, 1 patient)
Fatigue (below serious, 17 patients)
Oedema peripheral (below serious, 13 patients)
Pyrexia (below serious, 16 patients)
Influenza like illness (below serious, 5 patients)
Oedema (below serious, 4 patients)
Pain (below serious, 4 patients)
Neutropenia (below serious, 57 patients)
Leukopenia (below serious, 8 patients)
Thrombocytopenia (below serious, 36 patients)
Nasopharyngitis (below serious, 16 patients)
Upper respiratory tract infection (below serious, 12 patients)
Urinary tract infection (below serious, 12 patients)
Bronchitis (below serious, 14 patients)
Cystitis (below serious, 4 patients)
Lower respiratory tract infection (below serious, 5 patients)
Respiratory tract infection (below serious, 3 patients)
Sinusitis (below serious, 6 patients)
Gastroenteritis (below serious, 6 patients)
Influenza (below serious, 5 patients)
Pharyngitis (below serious, 4 patients)
Rhinitis (below serious, 3 patients)
Headache (below serious, 14 patients)
Dizziness (below serious, 10 patients)
Sciatica (below serious, 4 patients)
Balance disorder (below serious, 4 patients)
Peripheral sensory neuropathy (below serious, 1 patient)
Muscle spasms (below serious, 15 patients)
Back pain (below serious, 8 patients)
Myalgia (below serious, 6 patients)
Arthralgia (below serious, 5 patients)
Pain in extremity (below serious, 10 patients)
Musculoskeletal chest pain (below serious, 5 patients)
Neck pain (below serious, 3 patients)
Decreased appetite (below serious, 8 patients)
Iron overload (below serious, 5 patients)
Hypoalbuminaemia (below serious, 1 patient)
Hypokalaemia (below serious, 3 patients)
Hypomagnesaemia (below serious, 3 patients)
Cough (below serious, 10 patients)
Dyspnoea (below serious, 9 patients)
Epistaxis (below serious, 4 patients)
Dyspnoea exertional (below serious, 3 patients)
Oropharyngeal pain (below serious, 6 patients)
Pruritus (below serious, 20 patients)
Dry skin (below serious, 10 patients)
Rash (below serious, 12 patients)
Alopecia (below serious, 4 patients)
Hyperhidrosis (below serious, 4 patients)
Petechiae (below serious, 4 patients)
Insomnia (below serious, 9 patients)
Anxiety (below serious, 5 patients)
Contusion (below serious, 4 patients)
Fall (below serious, 4 patients)
Joint sprain (below serious, 1 patient)
Wound (below serious, 4 patients)
Alanine aminotransferase increased (below serious, 5 patients)
Weight decreased (below serious, 5 patients)
Haematoma (below serious, 6 patients)
Phlebitis (below serious, 4 patients)
Hypertension (below serious, 9 patients)
Cataract (below serious, 5 patients)
Conjunctivitis (below serious, 5 patients)
Dysuria (below serious, 3 patients)
Vertigo (below serious, 3 patients)
Musculoskeletal pain (below serious, 11 patient)
Sources:
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
n = 4
Health Status: unhealthy
Condition: Mantle Cell Lymphoma
Population Size: 4
Sources:
Other AEs: Squamous cell carcinoma, Herpes zoster...
Other AEs:
Squamous cell carcinoma (serious, 1 patient)
Herpes zoster (below serious, 1 patient)
Herpes zoster ophthalmic (below serious, 1 patient)
Viral rash (below serious, 1 patient)
Thrombocytopenia (below serious, 1 patient)
Neutropenia (below serious, 1 patient)
Constipation (below serious, 1 patient)
Abdominal pain upper (below serious, 1 patient)
Diarrhoea (below serious, 1 patient)
Dry mouth (below serious, 1 patient)
Flatulence (below serious, 1 patient)
Stomatitis (below serious, 1 patient)
Chills (below serious, 1 patient)
Oedema peripheral (below serious, 1 patient)
Dysgeusia (below serious, 1 patient)
Peripheral sensory neuropathy (below serious, 1 patient)
Eczema (below serious, 1 patient)
Rash (below serious, 1 patient)
Conjunctivitis (below serious, 1 patient)
Muscle spasms (below serious, 1 patient)
Neck pain (below serious, 1 patient)
Basal cell carcinoma (below serious, 1 patient)
Malignant melanoma (below serious, 1 patient)
Libido decreased (below serious, 1 patient)
Erectile dysfunction (below serious, 1 patient)
Sources:
25 mg 1 times / day steady, oral
Dose: 25 mg, 1 times / day
Route: oral
Route: steady
Dose: 25 mg, 1 times / day
Sources:
unhealthy
n = 22
Health Status: unhealthy
Condition: Plasma Cell Dyscrasias
Population Size: 22
Sources:
Other AEs: Bleeding, Ischemic colitis...
Other AEs:
Bleeding (serious, 1 patient)
Ischemic colitis (serious, 1 patient)
Sources:
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Other AEs: Pyrexia, Generalised oedema...
Other AEs:
Pyrexia (serious, 5 patients)
Generalised oedema (serious, 1 patient)
Non-cardiac chest pain (serious, 1 patient)
Pneumonia (serious, 5 patients)
Erysipelas (serious, 1 patient)
Gastroenteritis (serious, 1 patient)
Infection (serious, 1 patient)
Lower respiratory tract infection (serious, 1 patient)
Respiratory tract infection (serious, 1 patient)
Staphylococcal sepsis (serious, 1 patient)
Urinary tract infection (serious, 3 patients)
Urosepsis (serious, 1 patient)
Chronic obstructive pulmonary disease (serious, 1 patient)
Hypoxia (serious, 1 patient)
Lung disorder (serious, 1 patient)
Aspiration pneumonia (serious, 1 patient)
Pulmonary embolism (serious, 3 patients)
Respiratory failure (serious, 1 patient)
Acute myeloid leukaemia (serious, 8 patients)
Leukaemia (serious, 1 patient)
Lung cancer metastatic (serious, 1 patient)
Myelodysplastic syndrome (serious, 1 patient)
Refractory anaemia with an excess of blasts (serious, 1 patient)
Anxiety disorder (serious, 1 patient)
Altered mood (serious, 1 patient)
Atrial fibrillation (serious, 2 patients)
Cardiac failure (serious, 2 patients)
Diarrhoea (serious, 1 patient)
Intussusception (serious, 1 patient)
Tooth disorder (serious, 1 patient)
Fall (serious, 1 patient)
Injury (serious, 1 patient)
Transfusion reaction (serious, 1 patient)
Diabetes mellitus inadequate control (serious, 1 patient)
Hyperglycaemia (serious, 1 patient)
Hypoglycaemia (serious, 1 patient)
Headache (serious, 1 patient)
Renal failure (serious, 1 patient)
Urinary incontinence (serious, 1 patient)
Phlebitis (serious, 1 patient)
Venous thrombosis (serious, 1 patient)
Anaemia (serious, 4 patients)
Febrile neutropenia (serious, 2 patients)
Neutropenia (serious, 5 patients)
Pancytopenia (serious, 1 patient)
Thrombocytopenia (serious, 6 patients)
International normalised ratio increased (serious, 1 patient)
Urine human chorionic gonadotropin abnormal (serious, 1 patient)
Fibromyalgia (serious, 1 patient)
Muscle spasms (serious, 1 patient)
Myalgia (serious, 1 patient)
Pyoderma gangrenosum (serious, 1 patient)
Cytogenetic abnormality (serious, 1 patient)
Diarrhoea (below serious, 32 patients)
Nausea (below serious, 16 patients)
Constipation (below serious, 18 patients)
Abdominal pain (below serious, 7 patients)
Vomiting (below serious, 8 patients)
Dry mouth (below serious, 4 patients)
Abdominal pain upper (below serious, 8 patients)
Dyspepsia (below serious, 4 patients)
Flatulence (below serious, 2 patients)
Fatigue (below serious, 17 patients)
Oedema peripheral (below serious, 15 patients)
Pyrexia (below serious, 11 patient)
Non-cardiac chest pain (below serious, 5 patients)
Influenza like illness (below serious, 5 patients)
Oedema (below serious, 3 patients)
Pain (below serious, 1 patient)
Neutropenia (below serious, 55 patients)
Anaemia (below serious, 10 patients)
Leukopenia (below serious, 12 patients)
Thrombocytopenia (below serious, 38 patients)
Nasopharyngitis (below serious, 15 patients)
Upper respiratory tract infection (below serious, 11 patient)
Urinary tract infection (below serious, 6 patients)
Bronchitis (below serious, 7 patients)
Cystitis (below serious, 2 patients)
Lower respiratory tract infection (below serious, 2 patients)
Respiratory tract infection (below serious, 9 patients)
Gastroenteritis (below serious, 7 patients)
Gastroenteritis viral (below serious, 4 patients)
Influenza (below serious, 5 patients)
Oral herpes (below serious, 6 patients)
Pharyngitis (below serious, 3 patients)
Rhinitis (below serious, 4 patients)
Headache (below serious, 12 patients)
Dizziness (below serious, 8 patients)
Paraesthesia (below serious, 8 patients)
Peripheral sensory neuropathy (below serious, 4 patients)
Muscle spasms (below serious, 12 patients)
Back pain (below serious, 12 patients)
Myalgia (below serious, 4 patients)
Arthralgia (below serious, 6 patients)
Pain in extremity (below serious, 5 patients)
Musculoskeletal chest pain (below serious, 1 patient)
Neck pain (below serious, 3 patients)
Decreased appetite (below serious, 8 patients)
Iron overload (below serious, 4 patients)
Hypoalbuminaemia (below serious, 4 patients)
Hypokalaemia (below serious, 7 patients)
Hypomagnesaemia (below serious, 3 patients)
Cough (below serious, 12 patients)
Dyspnoea (below serious, 12 patients)
Epistaxis (below serious, 3 patients)
Dyspnoea exertional (below serious, 4 patients)
Oropharyngeal pain (below serious, 7 patients)
Pruritus (below serious, 16 patients)
Dry skin (below serious, 10 patients)
Rash (below serious, 18 patients)
Hyperhidrosis (below serious, 2 patients)
Petechiae (below serious, 3 patients)
Insomnia (below serious, 6 patients)
Depression (below serious, 4 patients)
Anxiety (below serious, 3 patients)
Contusion (below serious, 3 patients)
Fall (below serious, 2 patients)
Wound (below serious, 2 patients)
Alanine aminotransferase increased (below serious, 7 patients)
Weight decreased (below serious, 6 patients)
Haematoma (below serious, 6 patients)
Hypertension (below serious, 7 patients)
Cataract (below serious, 1 patient)
Vertigo (below serious, 8 patients)
Musculoskeletal pain (below serious, 5 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Birth defects serious
10 mg 1 times / day steady, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
pregnant, adult
Health Status: pregnant
Age Group: adult
Sex: F
Sources:
Abdominal pain NOS 0.5%
Disc. AE
10 mg 1 times / day steady, oral (starting)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources: Page: p. 101
unhealthy, adult
n = 395
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 395
Sources: Page: p. 101
Anemia hemolytic (NOS) 0.5%
Disc. AE
10 mg 1 times / day steady, oral (starting)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources: Page: p. 101
unhealthy, adult
n = 395
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 395
Sources: Page: p. 101
Arthralgia 0.5%
Disc. AE
10 mg 1 times / day steady, oral (starting)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources: Page: p. 101
unhealthy, adult
n = 395
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 395
Sources: Page: p. 101
Cough 0.5%
Disc. AE
10 mg 1 times / day steady, oral (starting)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources: Page: p. 101
unhealthy, adult
n = 395
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 395
Sources: Page: p. 101
Face edema 0.5%
Disc. AE
10 mg 1 times / day steady, oral (starting)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources: Page: p. 101
unhealthy, adult
n = 395
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 395
Sources: Page: p. 101
Pruritus 0.5%
Disc. AE
10 mg 1 times / day steady, oral (starting)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources: Page: p. 101
unhealthy, adult
n = 395
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 395
Sources: Page: p. 101
Dyspnea 0.8%
Disc. AE
10 mg 1 times / day steady, oral (starting)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources: Page: p. 101
unhealthy, adult
n = 395
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 395
Sources: Page: p. 101
Pyrexia 0.8%
Disc. AE
10 mg 1 times / day steady, oral (starting)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources: Page: p. 101
unhealthy, adult
n = 395
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 395
Sources: Page: p. 101
Abdominal distension 1%
Disc. AE
10 mg 1 times / day steady, oral (starting)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources: Page: p. 101
unhealthy, adult
n = 395
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 395
Sources: Page: p. 101
Anaemia NOS 1%
Disc. AE
10 mg 1 times / day steady, oral (starting)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources: Page: p. 101
unhealthy, adult
n = 395
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 395
Sources: Page: p. 101
Fatigue 1%
Disc. AE
10 mg 1 times / day steady, oral (starting)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources: Page: p. 101
unhealthy, adult
n = 395
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 395
Sources: Page: p. 101
Pneumonia NOS 1%
Disc. AE
10 mg 1 times / day steady, oral (starting)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources: Page: p. 101
unhealthy, adult
n = 395
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 395
Sources: Page: p. 101
Diarrhea 1.3%
Disc. AE
10 mg 1 times / day steady, oral (starting)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources: Page: p. 101
unhealthy, adult
n = 395
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 395
Sources: Page: p. 101
Nausea 1.5%
Disc. AE
10 mg 1 times / day steady, oral (starting)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources: Page: p. 101
unhealthy, adult
n = 395
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 395
Sources: Page: p. 101
Rash 2%
Disc. AE
10 mg 1 times / day steady, oral (starting)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources: Page: p. 101
unhealthy, adult
n = 395
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 395
Sources: Page: p. 101
Neutropenia 3.5%
Disc. AE
10 mg 1 times / day steady, oral (starting)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources: Page: p. 101
unhealthy, adult
n = 395
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 395
Sources: Page: p. 101
Thrombocytopenia 6.1%
Disc. AE
10 mg 1 times / day steady, oral (starting)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources: Page: p. 101
unhealthy, adult
n = 395
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 395
Sources: Page: p. 101
Neutropenia
10 mg 1 times / day steady, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Pulmonary embolism
10 mg 1 times / day steady, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Thrombocytopenia
10 mg 1 times / day steady, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Thrombosis venous deep
10 mg 1 times / day steady, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Diarrhoea NOS below serious, 11 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 87
Health Status: unhealthy
Condition: Complex Regional Pain Syndrome
Population Size: 87
Sources:
Rash NOS below serious, 24 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 87
Health Status: unhealthy
Condition: Complex Regional Pain Syndrome
Population Size: 87
Sources:
Alanine aminotransferase increased below serious, 5 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 87
Health Status: unhealthy
Condition: Complex Regional Pain Syndrome
Population Size: 87
Sources:
Cramp muscle below serious, 5 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 87
Health Status: unhealthy
Condition: Complex Regional Pain Syndrome
Population Size: 87
Sources:
Sinusitis NOS below serious, 5 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 87
Health Status: unhealthy
Condition: Complex Regional Pain Syndrome
Population Size: 87
Sources:
Vomiting NOS below serious, 5 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 87
Health Status: unhealthy
Condition: Complex Regional Pain Syndrome
Population Size: 87
Sources:
Dry skin below serious, 6 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 87
Health Status: unhealthy
Condition: Complex Regional Pain Syndrome
Population Size: 87
Sources:
Nasopharyngitis below serious, 6 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 87
Health Status: unhealthy
Condition: Complex Regional Pain Syndrome
Population Size: 87
Sources:
Pharyngitis below serious, 6 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 87
Health Status: unhealthy
Condition: Complex Regional Pain Syndrome
Population Size: 87
Sources:
Pyrexia below serious, 6 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 87
Health Status: unhealthy
Condition: Complex Regional Pain Syndrome
Population Size: 87
Sources:
Insomnia below serious, 7 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 87
Health Status: unhealthy
Condition: Complex Regional Pain Syndrome
Population Size: 87
Sources:
Constipation below serious, 8 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 87
Health Status: unhealthy
Condition: Complex Regional Pain Syndrome
Population Size: 87
Sources:
Pruritus below serious, 8 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 87
Health Status: unhealthy
Condition: Complex Regional Pain Syndrome
Population Size: 87
Sources:
Dizziness below serious, 9 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 87
Health Status: unhealthy
Condition: Complex Regional Pain Syndrome
Population Size: 87
Sources:
Abortion spontaneous NOS serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 87
Health Status: unhealthy
Condition: Complex Regional Pain Syndrome
Population Size: 87
Sources:
Angioneurotic edema serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 87
Health Status: unhealthy
Condition: Complex Regional Pain Syndrome
Population Size: 87
Sources:
Arthritis NOS serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 87
Health Status: unhealthy
Condition: Complex Regional Pain Syndrome
Population Size: 87
Sources:
Blood human chorionic gonadotropin positive serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 87
Health Status: unhealthy
Condition: Complex Regional Pain Syndrome
Population Size: 87
Sources:
Blood potassium decreased serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 87
Health Status: unhealthy
Condition: Complex Regional Pain Syndrome
Population Size: 87
Sources:
Foot fracture serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 87
Health Status: unhealthy
Condition: Complex Regional Pain Syndrome
Population Size: 87
Sources:
Pain NOS serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 87
Health Status: unhealthy
Condition: Complex Regional Pain Syndrome
Population Size: 87
Sources:
Pregnancy test false positive serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 87
Health Status: unhealthy
Condition: Complex Regional Pain Syndrome
Population Size: 87
Sources:
Sick sinus syndrome serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 87
Health Status: unhealthy
Condition: Complex Regional Pain Syndrome
Population Size: 87
Sources:
Thrombosis serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 87
Health Status: unhealthy
Condition: Complex Regional Pain Syndrome
Population Size: 87
Sources:
Joint sprain serious, 2 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 87
Health Status: unhealthy
Condition: Complex Regional Pain Syndrome
Population Size: 87
Sources:
Pregnancy NOS serious, 2 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 87
Health Status: unhealthy
Condition: Complex Regional Pain Syndrome
Population Size: 87
Sources:
Flatulence below serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Hypoalbuminaemia below serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Joint sprain below serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Peripheral sensory neuropathy below serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Cough below serious, 10 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Dizziness below serious, 10 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Dry skin below serious, 10 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Pain in extremity below serious, 10 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Musculoskeletal pain below serious, 11 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Rash below serious, 12 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Upper respiratory tract infection below serious, 12 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Urinary tract infection below serious, 12 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Oedema peripheral below serious, 13 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Abdominal pain below serious, 14 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Bronchitis below serious, 14 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Headache below serious, 14 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Muscle spasms below serious, 15 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Nasopharyngitis below serious, 16 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Pyrexia below serious, 16 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Fatigue below serious, 17 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Constipation below serious, 19 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Pruritus below serious, 20 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Nausea below serious, 21 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Dyspnoea exertional below serious, 3 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Dysuria below serious, 3 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Hypokalaemia below serious, 3 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Hypomagnesaemia below serious, 3 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Neck pain below serious, 3 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Respiratory tract infection below serious, 3 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Rhinitis below serious, 3 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Vertigo below serious, 3 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Thrombocytopenia below serious, 36 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Diarrhoea below serious, 37 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Alopecia below serious, 4 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Balance disorder below serious, 4 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Contusion below serious, 4 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Cystitis below serious, 4 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Epistaxis below serious, 4 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Fall below serious, 4 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Hyperhidrosis below serious, 4 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Oedema below serious, 4 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Pain below serious, 4 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Petechiae below serious, 4 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Pharyngitis below serious, 4 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Phlebitis below serious, 4 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Sciatica below serious, 4 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Wound below serious, 4 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Alanine aminotransferase increased below serious, 5 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Anxiety below serious, 5 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Arthralgia below serious, 5 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Cataract below serious, 5 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Conjunctivitis below serious, 5 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Dry mouth below serious, 5 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Dyspepsia below serious, 5 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Influenza like illness below serious, 5 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Influenza below serious, 5 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Iron overload below serious, 5 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Lower respiratory tract infection below serious, 5 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Musculoskeletal chest pain below serious, 5 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Weight decreased below serious, 5 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Neutropenia below serious, 57 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Gastroenteritis below serious, 6 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Haematoma below serious, 6 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Myalgia below serious, 6 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Oropharyngeal pain below serious, 6 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Sinusitis below serious, 6 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Abdominal pain upper below serious, 8 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Back pain below serious, 8 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Decreased appetite below serious, 8 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Leukopenia below serious, 8 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Dyspnoea below serious, 9 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Hypertension below serious, 9 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Insomnia below serious, 9 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Vomiting below serious, 9 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Abdominal pain upper serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Abdominal pain serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Altered mood serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Anaemia serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Anal abscess serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Arterial occlusive disease serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Arthritis serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Autoimmune thrombocytopenia serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Bacteraemia serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Bladder cancer serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Bone marrow failure serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Breast cancer serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Cardiac failure serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Cellulitis serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Cerebral haemorrhage serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Cerebrovascular accident serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Colic renal serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Colitis serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Colon cancer serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Colorectal cancer serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Coma serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Confusional state serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Constipation serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Delirium serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Epistaxis serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Erysipelas serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Fatigue serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Femoral neck fracture serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Gastroenteritis serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Haemolysis serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Headache serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Histiocytosis haematophagic serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Humerus fracture serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Hyperglycaemia serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Hypotension serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Intestinal obstruction serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Joint range of motion decreased serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Lung disorder serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Mucosal inflammation serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Musculoskeletal pain serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Myocardial infarction serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Orthostatic hypotension serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Pancytopenia serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Pneumonia legionella serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Pyelonephritis serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Renal failure serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Skin ulcer serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Spinal compression fracture serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Splenomegaly serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Stress urinary incontinence serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Subdural haematoma serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Synovial rupture serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Tachyarrhythmia serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Urinary tract infection serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Urticaria serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Acute myocardial infarction serious, 2 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Back pain serious, 2 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Febrile neutropenia serious, 2 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
General physical health deterioration serious, 2 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Pulmonary embolism serious, 2 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Refractory anaemia with an excess of blasts serious, 2 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Septic shock serious, 2 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Diarrhoea serious, 3 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Pneumonia serious, 3 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Thrombocytopenia serious, 3 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Deep vein thrombosis serious, 4 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Neutropenia serious, 5 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Acute myeloid leukaemia serious, 8 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Abdominal pain upper below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
n = 4
Health Status: unhealthy
Condition: Mantle Cell Lymphoma
Population Size: 4
Sources:
Basal cell carcinoma below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
n = 4
Health Status: unhealthy
Condition: Mantle Cell Lymphoma
Population Size: 4
Sources:
Chills below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
n = 4
Health Status: unhealthy
Condition: Mantle Cell Lymphoma
Population Size: 4
Sources:
Conjunctivitis below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
n = 4
Health Status: unhealthy
Condition: Mantle Cell Lymphoma
Population Size: 4
Sources:
Constipation below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
n = 4
Health Status: unhealthy
Condition: Mantle Cell Lymphoma
Population Size: 4
Sources:
Diarrhoea below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
n = 4
Health Status: unhealthy
Condition: Mantle Cell Lymphoma
Population Size: 4
Sources:
Dry mouth below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
n = 4
Health Status: unhealthy
Condition: Mantle Cell Lymphoma
Population Size: 4
Sources:
Dysgeusia below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
n = 4
Health Status: unhealthy
Condition: Mantle Cell Lymphoma
Population Size: 4
Sources:
Eczema below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
n = 4
Health Status: unhealthy
Condition: Mantle Cell Lymphoma
Population Size: 4
Sources:
Erectile dysfunction below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
n = 4
Health Status: unhealthy
Condition: Mantle Cell Lymphoma
Population Size: 4
Sources:
Flatulence below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
n = 4
Health Status: unhealthy
Condition: Mantle Cell Lymphoma
Population Size: 4
Sources:
Herpes zoster ophthalmic below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
n = 4
Health Status: unhealthy
Condition: Mantle Cell Lymphoma
Population Size: 4
Sources:
Herpes zoster below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
n = 4
Health Status: unhealthy
Condition: Mantle Cell Lymphoma
Population Size: 4
Sources:
Libido decreased below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
n = 4
Health Status: unhealthy
Condition: Mantle Cell Lymphoma
Population Size: 4
Sources:
Malignant melanoma below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
n = 4
Health Status: unhealthy
Condition: Mantle Cell Lymphoma
Population Size: 4
Sources:
Muscle spasms below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
n = 4
Health Status: unhealthy
Condition: Mantle Cell Lymphoma
Population Size: 4
Sources:
Neck pain below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
n = 4
Health Status: unhealthy
Condition: Mantle Cell Lymphoma
Population Size: 4
Sources:
Neutropenia below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
n = 4
Health Status: unhealthy
Condition: Mantle Cell Lymphoma
Population Size: 4
Sources:
Oedema peripheral below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
n = 4
Health Status: unhealthy
Condition: Mantle Cell Lymphoma
Population Size: 4
Sources:
Peripheral sensory neuropathy below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
n = 4
Health Status: unhealthy
Condition: Mantle Cell Lymphoma
Population Size: 4
Sources:
Rash below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
n = 4
Health Status: unhealthy
Condition: Mantle Cell Lymphoma
Population Size: 4
Sources:
Stomatitis below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
n = 4
Health Status: unhealthy
Condition: Mantle Cell Lymphoma
Population Size: 4
Sources:
Thrombocytopenia below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
n = 4
Health Status: unhealthy
Condition: Mantle Cell Lymphoma
Population Size: 4
Sources:
Viral rash below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
n = 4
Health Status: unhealthy
Condition: Mantle Cell Lymphoma
Population Size: 4
Sources:
Squamous cell carcinoma serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
n = 4
Health Status: unhealthy
Condition: Mantle Cell Lymphoma
Population Size: 4
Sources:
Bleeding serious, 1 patient
25 mg 1 times / day steady, oral
Dose: 25 mg, 1 times / day
Route: oral
Route: steady
Dose: 25 mg, 1 times / day
Sources:
unhealthy
n = 22
Health Status: unhealthy
Condition: Plasma Cell Dyscrasias
Population Size: 22
Sources:
Ischemic colitis serious, 1 patient
25 mg 1 times / day steady, oral
Dose: 25 mg, 1 times / day
Route: oral
Route: steady
Dose: 25 mg, 1 times / day
Sources:
unhealthy
n = 22
Health Status: unhealthy
Condition: Plasma Cell Dyscrasias
Population Size: 22
Sources:
Cataract below serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Musculoskeletal chest pain below serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Pain below serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Anaemia below serious, 10 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Dry skin below serious, 10 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Pyrexia below serious, 11 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Upper respiratory tract infection below serious, 11 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Back pain below serious, 12 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Cough below serious, 12 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Dyspnoea below serious, 12 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Headache below serious, 12 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Leukopenia below serious, 12 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Muscle spasms below serious, 12 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Nasopharyngitis below serious, 15 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Oedema peripheral below serious, 15 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Nausea below serious, 16 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Pruritus below serious, 16 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Fatigue below serious, 17 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Constipation below serious, 18 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Rash below serious, 18 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Cystitis below serious, 2 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Fall below serious, 2 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Flatulence below serious, 2 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Hyperhidrosis below serious, 2 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Lower respiratory tract infection below serious, 2 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Wound below serious, 2 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Anxiety below serious, 3 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Contusion below serious, 3 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Epistaxis below serious, 3 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Hypomagnesaemia below serious, 3 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Neck pain below serious, 3 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Oedema below serious, 3 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Petechiae below serious, 3 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Pharyngitis below serious, 3 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Diarrhoea below serious, 32 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Thrombocytopenia below serious, 38 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Depression below serious, 4 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Dry mouth below serious, 4 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Dyspepsia below serious, 4 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Dyspnoea exertional below serious, 4 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Gastroenteritis viral below serious, 4 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Hypoalbuminaemia below serious, 4 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Iron overload below serious, 4 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Myalgia below serious, 4 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Peripheral sensory neuropathy below serious, 4 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Rhinitis below serious, 4 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Influenza like illness below serious, 5 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Influenza below serious, 5 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Musculoskeletal pain below serious, 5 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Non-cardiac chest pain below serious, 5 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Pain in extremity below serious, 5 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Neutropenia below serious, 55 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Arthralgia below serious, 6 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Haematoma below serious, 6 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Insomnia below serious, 6 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Oral herpes below serious, 6 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Urinary tract infection below serious, 6 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Weight decreased below serious, 6 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Abdominal pain below serious, 7 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Alanine aminotransferase increased below serious, 7 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Bronchitis below serious, 7 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Gastroenteritis below serious, 7 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Hypertension below serious, 7 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Hypokalaemia below serious, 7 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Oropharyngeal pain below serious, 7 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Abdominal pain upper below serious, 8 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Decreased appetite below serious, 8 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Dizziness below serious, 8 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Paraesthesia below serious, 8 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Vertigo below serious, 8 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Vomiting below serious, 8 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Respiratory tract infection below serious, 9 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Altered mood serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Anxiety disorder serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Aspiration pneumonia serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Chronic obstructive pulmonary disease serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Cytogenetic abnormality serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Diabetes mellitus inadequate control serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Diarrhoea serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Erysipelas serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Fall serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Fibromyalgia serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Gastroenteritis serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Generalised oedema serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Headache serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Hyperglycaemia serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Hypoglycaemia serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Hypoxia serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Infection serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Injury serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
International normalised ratio increased serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Intussusception serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Leukaemia serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Lower respiratory tract infection serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Lung cancer metastatic serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Lung disorder serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Muscle spasms serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Myalgia serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Myelodysplastic syndrome serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Non-cardiac chest pain serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Pancytopenia serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Phlebitis serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Pyoderma gangrenosum serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Refractory anaemia with an excess of blasts serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Renal failure serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Respiratory failure serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Respiratory tract infection serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Staphylococcal sepsis serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Tooth disorder serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Transfusion reaction serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Urinary incontinence serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Urine human chorionic gonadotropin abnormal serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Urosepsis serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Venous thrombosis serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Atrial fibrillation serious, 2 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Cardiac failure serious, 2 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Febrile neutropenia serious, 2 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Pulmonary embolism serious, 3 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Urinary tract infection serious, 3 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Anaemia serious, 4 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Neutropenia serious, 5 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Pneumonia serious, 5 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Pyrexia serious, 5 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Thrombocytopenia serious, 6 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Acute myeloid leukaemia serious, 8 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
n = 69
Health Status: unhealthy
Condition: Myelodysplastic Syndrome
Population Size: 69
Sources:
Overview

Overview

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
inconclusive
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no (co-administration study)
Comment: enzyme marker ethoxyresorufin O-dealkylase was used
Page: 27.0
no
no (co-administration study)
Comment: enzyme marker S-mephenytoin 4-hydroxylase
Page: 27.0
no
no (co-administration study)
Comment: enzyme marker tolbutamide methyl-hydroxylase
Page: 27.0
no
no (co-administration study)
Comment: enzyme marker bufuralol 1-hydroxylase
Page: 27.0
no
no (co-administration study)
Comment: enzyme marker lauric acid 11-hjydroxylase
Page: 27.0
no
no (co-administration study)
Comment: enzyme marker testosterone 6b-hydroxylase
Page: 27.0
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
inconclusive
no
no
no
no
no
no
no
no
no
no
no
no
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
New treatments for multiple myeloma.
2005 Dec
Lenalidomide and thalidomide: mechanisms of action--similarities and differences.
2005 Oct
Lenalidomide-induced warm autoimmune hemolytic anemia.
2006 Dec 10
Current therapeutic uses of lenalidomide in multiple myeloma.
2006 Feb
Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications.
2006 Jul 15
Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis.
2006 Mar 1
Lenalidomide: a new agent for patients with relapsed or refractory multiple myeloma.
2007 Aug
Risk of thrombosis with lenalidomide and its prevention with aspirin.
2007 Jan
Thromboembolic events with lenalidomide-based therapy for multiple myeloma.
2008 Apr 1
Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.
2008 Feb
Azotemia associated with use of lenalidomide in plasma cell dyscrasias.
2008 Jun
Development of rapid light-chain deposition disease in hepatic arteries with severe ischemic cholangitis in a multiple myeloma patient treated with melphalan, prednisone and lenalidomide.
2009 Jan
Rapid control of previously untreated multiple myeloma with bortezomib-lenalidomide-dexamethasone (BLD).
2010 Apr
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
2010 Aug 5
Altered expression of signalling lymphocyte activation molecule (SLAM) family receptors CS1 (CD319) and 2B4 (CD244) in patients with systemic lupus erythematosus.
2010 Jun
Renal recovery with lenalidomide in a patient with bortezomib-resistant multiple myeloma.
2010 May
Stroke after treatment with bortezomib and dexamethasone in a Chinese patient with extramedullary relapse of multiple myeloma.
2010 Nov
Activation of coagulation by lenalidomide-based regimens for the treatment of multiple myeloma.
2013
Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide.
2014 Aug 7
"Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group.
2014 Jan
The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma.
2014 Jan 16
Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis.
2015 May 18
Patents

Patents

Sample Use Guides

Multiple Myeloma: REVLIMID ([lenalidomide capsules) 25 mg once daily on Days 1-21 of repeated 28-day cycles. The recommended dose of dexamethasone is 40 mg once daily on Days 1-4, 9-12, and 17-20 of each 28-day cycle for the first 4 cycles of therapy and then 40 mg once daily orally on Days 1-4 every 28 days. Treatment is continued or modified based upon clinical and laboratory findings Myelodysplastic Syndromes: The recommended starting dose of REVLIMID is 10 mg daily Mantle Cell Lymphoma: The recommended starting dose of REVLIMID is 25 mg/day orally on Days 1-21 of repeated 28-day cycles for relapsed or refractory mantle cell lymphoma
Route of Administration: Oral
Lenalidomide enhances signaling via CAR19 receptor. To determine the costimulatory effect of lenalidomide, CAR19 T cells were stimulated with immobilized anti-CD3 antibody (clone MEM-57) or, with immobilized anti-CAR serum (polyclonal goat anti-mouse IgG FAB2) in the presence (10 MM, 1 MM) or absence of lenalidomide. The production of IFN in to culture supernatant was determined with ELISA after overnight co-incubation
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:27:53 UTC 2021
Edited
by admin
on Fri Jun 25 21:27:53 UTC 2021
Record UNII
F0P408N6V4
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LENALIDOMIDE
EMA EPAR   INN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
LENALIDOMIDE [EMA EPAR]
Common Name English
LENALIDOMIDE [ORANGE BOOK]
Common Name English
REVLIMID
Brand Name English
LENALIDOMIDE [INN]
Common Name English
LENALIDOMIDE [VANDF]
Common Name English
2,6-PIPERIDINEDIONE, 3-(4-AMINO-1,3-DIHYDRO-1-OXO-2H-ISOINDOL-2-YL)-
Systematic Name English
LENALIDOMIDE [MART.]
Common Name English
NSC-747972
Code English
CDC-501
Code English
LENALIDOMIDE [MI]
Common Name English
3-(4-AMINO-1-OXO-1,3-DIHYDRO-2H-ISOINDOL-2-YL)PIPERIDINE-2,6-DIONE
Systematic Name English
SYP-1512
Code English
LENALIDOMIDE [USAN]
Common Name English
CC-5013
Code English
LENALIDOMIDE [WHO-DD]
Common Name English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS REVLIMID (AUTHORIZED: MULTIPLE MYELOMA)
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
NDF-RT N0000184014
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
FDA ORPHAN DRUG 476015
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
FDA ORPHAN DRUG 390813
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
FDA ORPHAN DRUG 147701
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
FDA ORPHAN DRUG 476115
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
FDA ORPHAN DRUG 230606
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
FDA ORPHAN DRUG 475915
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
FDA ORPHAN DRUG 180303
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
NCI_THESAURUS C1742
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
WHO-ATC L04AX04
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
NCI_THESAURUS C54677
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
EU-Orphan Drug EU/3/07/494
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
WHO-VATC QL04AX04
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
NCI_THESAURUS C129820
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
LIVERTOX 544
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
FDA ORPHAN DRUG 333811
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
FDA ORPHAN DRUG 278809
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
Code System Code Type Description
INN
8505
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
PRIMARY
PUBCHEM
216326
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
PRIMARY
DRUG CENTRAL
3317
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
PRIMARY
NCI_THESAURUS
C2668
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
PRIMARY
EVMPD
SUB25389
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
PRIMARY
EPA CompTox
191732-72-6
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
PRIMARY
RXCUI
342369
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
PRIMARY RxNorm
FDA UNII
F0P408N6V4
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
PRIMARY
CAS
191732-72-6
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
PRIMARY
HSDB
8220
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
PRIMARY
DRUG BANK
DB00480
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
PRIMARY
MERCK INDEX
M6760
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
PRIMARY Merck Index
MESH
C467567
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
PRIMARY
ChEMBL
CHEMBL848
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
PRIMARY
IUPHAR
7331
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
PRIMARY
WIKIPEDIA
LENALIDOMIDE
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
PRIMARY
Related Record Type Details
BINDER->LIGAND
BINDING
TARGET -> INHIBITOR
BINDING
TARGET -> INHIBITOR
CRBN ubiquitination studies in the transfected HEK293T cells resulted in the following potencies: CC-220 IC50 = 0.19 ?M; lenalidomide IC50 = 12.9 ?M; and pomalidomide IC50 = 21.6 ?M.
BINDING
IC50
SALT/SOLVATE -> PARENT
ENANTIOMER -> RACEMATE
ENANTIOMER -> RACEMATE
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC ORAL ADMINISTRATION

Biological Half-life PHARMACOKINETIC